The primary safety endpoint occurred in 9.8% of patients due to two deaths in the ViM (Valve in Mitral annular calcification) group and one death in the ViV (Valve in Valve) group. There were no ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

even after successful valve surgery. This is according to a new study, "Mitral annular disjunction and mitral valve prolapse: long-term risk of ventricular arrhythmias after surgery" from ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic ...

IRVINE, Calif., April 14, 2025--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the ...

The condition is more common in women and younger patients with valve disorder and can, in the worst case, lead to sudden cardiac arrest. Mitral annular disjunction, MAD, is a heart abnormality in ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up market rivalry with Abbott. Edwards’ device, dubbed Sapien M3 ...

The condition is more common in women and younger patients with valve disorder and can, in the worst case, lead to sudden cardiac arrest. Mitral annular disjunction, MAD, is a heart abnormality in ...

Nearly six years since the launch of the smash hit Valve Index, it appears the Steam team is gearing up to start making the long-awaited standalone sequel according to new rumors. Codenamed the ...